ACAD | Ticker Profile - Titan Protect

ACAD

ACADIA Pharmaceuticals Inc.

Healthcare · Biotechnology · NMS

$21.56

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$3.6B

Total market value of the company

Trailing P/E

9.59

Very cheap relative to earnings

Forward P/E

23.73

Based on estimated future earnings — lower means cheaper

Rev Growth

+9.7%

Year-over-year revenue change

Profit Margin

34.3%

How much profit the company keeps from each dollar of revenue

ROE

37.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$32.00

+48% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 20 analysts covering this stock

About ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

https://www.acadia.com

Country: United States Employees: 796 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.657

Good returns relative to risk taken

Kelly Fraction

0.0429

Modest edge detected — smaller position warranted

Calmar Ratio

0.714

Acceptable balance between returns and drawdown risk

Annual Return

21.8%

Historical annualised return based on price data

Max Drawdown

-30.5%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

169

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.86

Less volatile than the market — more defensive

52W High

$28.35

24% below the year high

52W Low

$19.69

9% above the year low

Avg Volume

1,831,463

Average daily shares traded — higher means easier to buy and sell

Short Ratio

6.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

10.6%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$2.21

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

4.07

Heavy leverage — higher financial risk if revenues decline

Current Ratio

3.59

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

3.27

Like current ratio but excludes inventory — stricter test

Gross Margin

61.6%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-1.7%

Profit from core operations before interest and tax

Free Cash Flow

$154M

Positive — the business generates more cash than it spends

Revenue (TTM)

$1.1B

Total revenue over the last 12 months

Net Income

$376M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$45.00

Target Median

$32.00

Target Low

$17.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go